Advanced maternal age markedly reduces blastocyst formation and live‑birth rates, linked to distinct age‑associated gene expression and metabolomic shifts in oocytes

The Question

Women increasingly delay childbearing, yet the biological underpinnings of age‑related fertility loss remain poorly defined. Researchers asked whether integrating clinical markers with molecular profiling could pinpoint the mechanisms that drive declining oocyte competence.

The Experiment

Lead investigator Kordowitzki and colleagues from the Department of Basic and Preclinical Sciences assembled a retrospective cohort of 400 women undergoing intracytoplasmic sperm injection (ICSI). Hormonal status (Anti‑Müllerian Hormone, Follicle‑Stimulating Hormone) and IVF outcomes (recovered oocytes, blastocyst formation, pregnancy, live birth) were extracted from medical records. Parallelly, RNA sequencing was performed on donated human oocytes spanning a wide age range, and untargeted mass‑spectrometry metabolomics profiled ovarian tissue from young versus reproductively aged mice.

What They Found

Comparisons between younger and older patients uncovered statistically significant reductions in blastocyst formation, clinical pregnancy, and live‑birth rates. Hormonal profiling showed lower AMH and higher FSH in the advanced‑age group. Transcriptomic analysis revealed a distinct set of age‑associated gene expression signatures in oocytes, while metabolomic profiling identified multiple metabolites whose abundance shifted with ovarian aging in the murine model.

Why It Matters

The decline in AMH and rise in FSH reflect diminished ovarian reserve, a well‑established clinical indicator of reproductive aging. The newly described gene‑expression signatures point to altered pathways such as mitochondrial function, DNA repair, and oxidative stress response—processes known to deteriorate with age. Corresponding metabolomic alterations suggest that the ovarian microenvironment becomes less supportive of oocyte maturation, potentially linking systemic metabolic shifts to the observed drop in blastocyst viability.

Study Limitations

• The human cohort was observational; causality between molecular changes and clinical outcomes cannot be established.


• Sample sizes for the RNA‑seq and mouse metabolomics components were not disclosed, limiting assessment of statistical power.


• Findings derive from a single fertility clinic, which may restrict generalizability to broader populations.

Practical Application

For healthy adults seeking to optimize reproductive timing, the data reinforce the advantage of earlier family planning when feasible. Women who are considering postponing pregnancy might monitor AMH and FSH levels as part of routine health assessments, recognizing that lower AMH and higher FSH correlate with reduced blastocyst formation and live‑birth probabilities. Beyond hormonal testing, no specific supplementation or intervention is justified solely by this study, as the molecular signatures identified have not yet been translated into actionable protocols.

Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.